CSL (OTCMKTS:CSLLY) Sees Large Volume Increase – Here’s What Happened

Shares of CSL Limited Sponsored ADR (OTCMKTS:CSLLY) saw an uptick in trading volume on Wednesday . 338,030 shares were traded during mid-day trading, an increase of 193% from the previous session’s volume of 115,402 shares.The stock last traded at $64.19 and had previously closed at $63.03.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Canaccord Genuity Group raised CSL from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 28th. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a research report on Monday, December 29th. Finally, Royal Bank Of Canada upgraded shares of CSL from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy”.

CSL Stock Performance

The company has a quick ratio of 1.12, a current ratio of 2.46 and a debt-to-equity ratio of 0.50. The business has a 50-day moving average of $59.77 and a 200-day moving average of $66.64.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.